THOUSAND OAKS, Calif.,
Oct. 4, 2021 /PRNewswire/ -- Amgen
(NASDAQ:AMGN) today announced results from real-world data in
Asia, Europe, Oceania, and North and South
America on the temporal trends in hip fracture incidence, and
in post-fracture pharmacological treatment intervention. The study,
presented as a late-breaking abstract at the American Society for
Bone and Mineral Research 2021 Annual Meeting (ASBMR), is titled
"Hip Fractures: Initial Report of Trends in Incidence,
Treatment, and Mortality In Multiple Countries Using a Common
Analytical Platform." The results of the study reveal
that hip fracture remains a significant public health issue across
the globe, and that the effects of aging populations and suboptimal
pharmacological treatment may contribute to an increasing burden of
osteoporosis.i
"Hip fractures represent a major public health crisis, but
previously available reports on incidence are based on decades old
data for some regions," said Darryl
Sleep, M.D., senior vice president of Global Medical and
chief medical officer at Amgen. "We are excited to present the
latest global data on hip fractures, which uses a unified
methodology that makes it possible to provide updated incidence, as
well as valuable insights on the risk factors and next steps in the
treatment of osteoporosis."
This study, led by the University of Hong
Kong, was funded by Amgen and includes Amgen
authors. This initial report, inclusive of years 2005 and
2018, is based on thirteen data sources from Australia, Canada, Germany, Hong
Kong, Italy, the Netherlands, New
Zealand, South Korea,
Spain, Taiwan, United
Kingdom, and two systems (Medicare and Optum's de–identified
Clinformatics® Data Mart Database) from
the United States.i
The change in age-standardized hip fracture incidence varied
from -2.1% to +2.3% per year across all data sources (HK, -2.1%;
UK, -1.3%; TW, -1.8%; IT, -1.4%; Spain, -1.1%; USM, -1.1%; Canada, -0.9%; NZ, -0.8%; USO, -0.2%; AU,
+0.2%; GE, +0.8%; SK, +0.8%; NL, +2.3%); those data sources with
full population coverage show the absolute number of hip fractures
per year has increased. Post-fracture care
with pharmacological treatment within 12 months after fracture
ranged from 11.5% to 50.3% across the globe, with recent annual
trends notably decreasing in some health care systems (e.g. United
States Medicare).i
"This study examined patients over 50 years old who were
hospitalized due to a hip fracture. Although hip fracture incidence
has been stabilized or reduced in many countries in recent years,
this reduction is insufficient to offset the increase of hip
fractures as the global population ages," said lead investigator,
Chor-Wing Sing, PhD, Department of
Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The
University of Hong Kong. "The current
results also show low post-hip fracture treatment rates, which
suggest that prevention efforts following hip fractures can be
improved. Such efforts are critical, given that following a hip
fracture, postmenopausal women are 2.5 times more likely to break
another bone." ii
About Osteoporosis-related Fractures
Worldwide, one in
three women and one in five men over the age of 50, will suffer a
fracture due to osteoporosis.iii Similarly, in the
U.S. one in two women over the age of 50 will experience a fracture
in her remaining lifetime due to
osteoporosis.iv Breaking a bone can be a
life-altering event that can lead to pain, loss of mobility and a
change in lifestyle.v
About Amgen
Amgen is committed to unlocking the potential of biology for
patients suffering from serious illnesses by discovering,
developing, manufacturing and delivering innovative human
therapeutics. This approach begins by using tools like advanced
human genetics to unravel the complexities of disease and
understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its
expertise to strive for solutions that improve health outcomes and
dramatically improve people's lives. A biotechnology pioneer since
1980, Amgen has grown to be one of the world's leading independent
biotechnology companies, has reached millions of patients around
the world and is developing a pipeline of medicines with breakaway
potential.
Amgen Forward-Looking Statements
This news release contains forward-looking statements that are
based on the current expectations and beliefs of Amgen. All
statements, other than statements of historical fact, are
statements that could be deemed forward-looking statements,
including any statements on the outcome, benefits and synergies of
collaborations, or potential collaborations, with any other company
(including BeiGene, Ltd., Kyowa-Kirin Co., Ltd., or any
collaboration to manufacture therapeutic antibodies against
COVID-19), the performance of Otezla (apremilast) (including
anticipated Otezla sales growth and the timing of non-GAAP EPS
accretion), or the Five Prime Therapeutics, Inc. acquisition, as
well as estimates of revenues, operating margins, capital
expenditures, cash, other financial metrics, expected legal,
arbitration, political, regulatory or clinical results or
practices, customer and prescriber patterns or practices,
reimbursement activities and outcomes, effects of pandemics or
other widespread health problems such as the ongoing COVID-19
pandemic on our business, outcomes, progress, or effects relating
to studies of Otezla as a potential treatment for COVID-19, and
other such estimates and results. Forward-looking statements
involve significant risks and uncertainties, including those
discussed below and more fully described in the Securities and
Exchange Commission reports filed by Amgen, including our most
recent annual report on Form 10-K and any subsequent periodic
reports on Form 10-Q and current reports on Form 8-K. Unless
otherwise noted, Amgen is providing this information as of the date
of this news release and does not undertake any obligation to
update any forward-looking statements contained in this document as
a result of new information, future events or otherwise.
No forward-looking statement can be guaranteed and actual
results may differ materially from those we project. Our results
may be affected by our ability to successfully market both new and
existing products domestically and internationally, clinical and
regulatory developments involving current and future products,
sales growth of recently launched products, competition from other
products including biosimilars, difficulties or delays in
manufacturing our products and global economic conditions. In
addition, sales of our products are affected by pricing pressure,
political and public scrutiny and reimbursement policies imposed by
third-party payers, including governments, private insurance plans
and managed care providers and may be affected by regulatory,
clinical and guideline developments and domestic and international
trends toward managed care and healthcare cost containment.
Furthermore, our research, testing, pricing, marketing and other
operations are subject to extensive regulation by domestic and
foreign government regulatory authorities. We or others could
identify safety, side effects or manufacturing problems with our
products, including our devices, after they are on the market. Our
business may be impacted by government investigations, litigation
and product liability claims. In addition, our business may be
impacted by the adoption of new tax legislation or exposure to
additional tax liabilities. If we fail to meet the compliance
obligations in the corporate integrity agreement between us and the
U.S. government, we could become subject to significant sanctions.
Further, while we routinely obtain patents for our products and
technology, the protection offered by our patents and patent
applications may be challenged, invalidated or circumvented by our
competitors, or we may fail to prevail in present and future
intellectual property litigation. We perform a substantial amount
of our commercial manufacturing activities at a few key facilities,
including in Puerto Rico, and also
depend on third parties for a portion of our manufacturing
activities, and limits on supply may constrain sales of certain of
our current products and product candidate development. An outbreak
of disease or similar public health threat, such as COVID-19, and
the public and governmental effort to mitigate against the spread
of such disease, could have a significant adverse effect on the
supply of materials for our manufacturing activities, the
distribution of our products, the commercialization of our product
candidates, and our clinical trial operations, and any such events
may have a material adverse effect on our product development,
product sales, business and results of operations. We rely on
collaborations with third parties for the development of some of
our product candidates and for the commercialization and sales of
some of our commercial products. In addition, we compete with other
companies with respect to many of our marketed products as well as
for the discovery and development of new products. Discovery or
identification of new product candidates or development of new
indications for existing products cannot be guaranteed and movement
from concept to product is uncertain; consequently, there can be no
guarantee that any particular product candidate or development of a
new indication for an existing product will be successful and
become a commercial product. Further, some raw materials, medical
devices and component parts for our products are supplied by sole
third-party suppliers. Certain of our distributors, customers and
payers have substantial purchasing leverage in their dealings with
us. The discovery of significant problems with a product similar to
one of our products that implicate an entire class of products
could have a material adverse effect on sales of the affected
products and on our business and results of operations. Our efforts
to collaborate with or acquire other companies, products or
technology, and to integrate the operations of companies or to
support the products or technology we have acquired, may not be
successful. A breakdown, cyberattack or information security breach
could compromise the confidentiality, integrity and availability of
our systems and our data. Our stock price is volatile and may be
affected by a number of events. Global economic conditions may
magnify certain risks that affect our business. Our business
performance could affect or limit the ability of our Board of
Directors to declare a dividend or our ability to pay a dividend or
repurchase our common stock. We may not be able to access the
capital and credit markets on terms that are favorable to us, or at
all.
CONTACT: Amgen, Thousand
Oaks
Michael Strapazon, 805-313-5553
(Media)
Megan Fox, 805-447-1423 (Media)
Arvind Sood, 805-447-1060
(Investors)
i Sing C, Lin T, Bartholomew S, et al. Hip Fractures:
Initial Report of Trends in Incidence, Treatment, and Mortality In
Multiple Countries Using a Common Analytical Platform. Abstract
presented at: American Society for Bone and Mineral Research Annual
Meeting, October 1-4, 2021;
San Diego, California.
ii Klotzbuecher CM, Ross, PD, Landsman, PB, et al.
Patients with Prior Fractures Have an Increased Risk of Future
Fractures: A Summary of the Literature and Statistical Synthesis.
JBMR. 2010; 15:4, 721-739.
iii International Osteoporosis Foundation. Facts and
Statistics. https://www.iofbonehealth.org/facts-statistics.
Accessed September 7, 2021.
iv National Osteoporosis Foundation. Osteoporosis Fast
Facts.
https://cdn.nof.org/wp-content/uploads/2015/12/Osteoporosis-Fast-Facts.pdf.
Accessed September 17, 2021.
v Cosman F, De beur SJ, Leboff MS, et al. Clinician's
Guide to Prevention and Treatment of Osteoporosis. Osteoporos
Int. 2014;25(10):2359-2381.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/amgen-announces-new-data-highlighting-global-trends-in-hip-fracture-incidence-and-treatment-301392106.html
SOURCE Amgen